Shares of biotech company InterMune Inc. (NASDAQ: ITMN) more than doubled Tuesday after the company said its experimental drug pirfenidone, in a late-stage trial, reduced the progression of a disease that leads to loss of lung function. You would think a move of this magnitude is from the company being acquired. This is no M&A story at all, at least not yet. InterMune Inc (NASDAQ:ITMN) stock opened at $35.69 in last session, and closed at $37.80, while the day range of ITMN stock is $30.32-$38-73.The stock showed a positive weekly performance of 170.77%.
Gilead Sciences, Inc. (NASDAQ:GILD)’s shares increased 1.19% to $83.57. The Gilead Sciences, Inc. (NASDAQ:GILD) on Feb. 10 announced that the Gilead Sciences, Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults. The data submitted in the NDA support the use of LDV/SOF in patients with genotype 1 hepatitis C virus (HCV) infection, with a treatment duration of eight or 12 weeks depending on prior treatment history and whether they have cirrhosis. Approximately 75 percent of people infected with HCV in the United States have the genotype 1 strain of the virus. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened at $84.14, in last session and closed at $83.95, by gained 0.45%.The 52 week range was $41.69-$84.88.Company’s market capitalization is $128.81 billion.
XOMA Corp (NASDAQ:XOMA) announced members of its management team are scheduled to present at Cowen and Company 34th Annual Health Care Conference on Mar. 4, 2014, at 10:00 a.m. ET at The Boston Marriott Copley Place; and 26th Annual ROTH Conference on Mar. 11, 2014, at 1:00 p.m. PT at The Ritz-Carlton, Laguna Niguel. XOMA Corp (NASDAQ:XOMA) stock gained 4.63% and finished the last session at $9.26.The EPS of the stock remained -0.80.Company’s market capitalization is $959.58 million.
Zacks lowered shares of Novo Nordisk (NYSE:NVO) from an outperform rating to a neutral rating in a report released on Monday, AnalystRatingsNetwork.com reports. Zacks currently has $45.00 price objective on the stock. Novo Nordisk A/S (ADR) (NYSE:NVO) stock opened the session at $47.11, and closed the session at $48.23.The 52 week range of the NVO stock remained $29.90-$48.42 and the day range was $47.08-$48.42.